Logo

American Heart Association

  15
  0


Final ID: MP948

Optimal hemodynamic status and prognostic predictors in patients with right ventricular dysfunction: the RIGHT study

Abstract Body (Do not enter title and authors here): Background: Optimal hemodynamics for right ventricular dysfunction (RVD) differs from those for left ventricular dysfunction. However, evidence regarding optimal hemodynamics and prognostic predictors of RVD remains limited, highlighting the need for further investigation.
Research Questions: What is the optimal hemodynamic status to increase cardiac output and what are the prognostic predictors in patients with right ventricular dysfunction?
Methods: This retrospective, single-center cohort study was conducted between 2014 and 2024. We analyzed data from patients diagnosed with RVD, defined as pulmonary artery pulse index ([sPAP–dPAP]/RAP) <1.85 and RAP/PAWP >0.63 based on right heart catheterization (RHC). Patients with left ventricular ejection fraction <50% were excluded. Two sub-studies were conducted: Study A assessed the relationship between cardiac index and hemodynamic parameters derived from RHC, and Study B investigated the prognostic value of hemodynamic parameters associated with RVD. The primary outcome in Study B was a composite of all-cause death and heart failure hospitalization.
Results: A total of 210 RHC examinations from 162 patients (median age 69 years) were analyzed. In Study A, a higher RAP was associated with increased cardiac output up to approximately 12 mmHg, beyond which further increases in RAP were associated with a decline in output, although the nonlinearity was not statistically significant. A higher heart rate was significantly associated with an increased cardiac output in patients with sinus rhythm, with a peak effect of approximately 80 bpm. In patients with atrial fibrillation, cardiac output increased steadily with rising heart rate. In Study B, 34 patients experienced the primary outcome during a median follow-up period of 505 days. Patients who experienced the primary outcome had higher heart rate, PAWP, and RAP, as well as a lower pulmonary artery compliance (PAC: stroke volume/[sPAP–dPAP]). Kaplan–Meier analysis demonstrated that PAC ≤ 4.5 mL/mmHg (median, p=0.02) and RAP > 10 mmHg (median, p=0.01) were associated with worse outcomes. In Cox proportional hazards analysis, PAC ≤ 4.5 mL/mmHg (HR 2.37; p=0.02) and RAP > 10 mmHg (HR 2.43; p=0.02) independently predicted the primary outcome after adjusting for age and sex.
Conclusions: In patients with RVD, optimal preload and heart rate contributed to increased cardiac output. Low PAC and high RAP were independent predictors of cardiac events in this population.
  • Suzuki, Sho  ( Shinshu University School of Medicine , Matsumoto , Nagano , Japan )
  • Oguchi, Yasutaka  ( Shinshu University School of Medicine , Matsumoto , Nagano , Japan )
  • Kato, Tamon  ( Shinshu University School of Medicine , Matsumoto , Nagano , Japan )
  • Saigusa, Tatsuya  ( Shinshu University School of Medicine , Matsumoto , Nagano , Japan )
  • Okada, Ayako  ( Shinshu University School of Medicine , Matsumoto , Nagano , Japan )
  • Ebisawa, Soichiro  ( Shinshu University School of Medicine , Matsumoto , Nagano , Japan )
  • Kuwahara, Koichiro  ( Shinshu University School of Medicine , Matsumoto , Nagano , Japan )
  • Nishikawa, Ken  ( Shinshu University School of Medicine , Matsumoto , Nagano , Japan )
  • Terashima, Takehiro  ( Shinshu University School of Medicine , Matsumoto , Nagano , Japan )
  • Minamisawa, Masatoshi  ( Shinshu University School of Medicine , Matsumoto , Nagano , Japan )
  • Yoshie, Koji  ( Shinshu University School of Medicine , Matsumoto , Nagano , Japan )
  • Aoki, Takenori  ( Shinshu University School of Medicine , Matsumoto , Nagano , Japan )
  • Okuma, Yukari  ( Shinshu University School of Medicine , Matsumoto , Nagano , Japan )
  • Kimura, Kazuhiro  ( Shinshu University School of Medicine , Matsumoto , Nagano , Japan )
  • Ueki, Yasushi  ( Shinshu University School of Medicine , Matsumoto , Nagano , Japan )
  • Author Disclosures:
    Sho Suzuki: DO have relevant financial relationships ; Speaker:Abbott Medical Japan LLC:Past (completed) ; Other (please indicate in the box next to the company name):MEDICAL VIEW CO., LTD., manuscript fees:Expected (by end of conference) ; Research Funding (PI or named investigator):Shinshu Public Utility Foundation for Promotion of Medical Sciences:Past (completed) ; Research Funding (PI or named investigator):AIBA WORKS Co., Ltd.:Past (completed) ; Other (please indicate in the box next to the company name):NIPPONRINSHOSHA Co., Ltd., manuscript fees:Past (completed) ; Other (please indicate in the box next to the company name):Shorinsha Co., Ltd, manuscript fees:Past (completed) ; Speaker:Otsuka Pharmaceutical Co., Ltd:Past (completed) ; Speaker:NIPRO CORPORATION:Past (completed) ; Speaker:Mallinckrodt Pharma K.K.:Past (completed) ; Speaker:Heart Organization Co., Ltd:Past (completed) ; Speaker:AstraZeneca PLC:Past (completed) ; Speaker:Abiomed Japan K.K:Past (completed) | Yasutaka Oguchi: No Answer | Tamon Kato: No Answer | Tatsuya Saigusa: DO NOT have relevant financial relationships | Ayako Okada: No Answer | Soichiro Ebisawa: No Answer | Koichiro Kuwahara: DO have relevant financial relationships ; Speaker:AstraZeneca K.K.:Active (exists now) ; Research Funding (PI or named investigator):Abbott Japan LLC,:Active (exists now) ; Research Funding (PI or named investigator):Boston Scientific Japan K.K:Active (exists now) ; Research Funding (PI or named investigator):Medtronic Japan Co. Ltd:Active (exists now) ; Research Funding (PI or named investigator):Astellas Pharma Inc.:Active (exists now) ; Research Funding (PI or named investigator):Biotronik Japan:Active (exists now) ; Research Funding (PI or named investigator):Cordis Japan G.K :Active (exists now) ; Research Funding (PI or named investigator):Terumo Corporation:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk Pharma Ltd.:Active (exists now) ; Speaker: Daiichi Sankyo Co., Ltd:Active (exists now) ; Research Funding (PI or named investigator):AstraZeneca K.K:Active (exists now) ; Research Funding (PI or named investigator):Kowa Co., Ltd:Active (exists now) ; Speaker:Janssen Pharmaceutical K.K:Active (exists now) ; Speaker:Pfizer Japan Inc:Active (exists now) ; Speaker: Bayer Yakuhin, Ltd.:Active (exists now) ; Speaker:Novo Nordisk Pharma Ltd.:Active (exists now) ; Speaker:Novartis Pharma K.K:Active (exists now) ; Speaker:Nippon Boehringer Ingelheim Co., Ltd.:Active (exists now) ; Speaker:Eli Lilly Japan K.K.:Active (exists now) ; Speaker:Mitsubishi Tanabe Pharma Corp.:Active (exists now) ; Speaker:Kowa Co., Ltd.:Active (exists now) ; Speaker:Kyowa Kirin Co., Ltd:Active (exists now) ; Speaker:Ono Pharmaceutical Co., Ltd:Active (exists now) ; Speaker:Otsuka Pharmaceutical Co., Ltd:Active (exists now) ; Speaker:MSD K.K:Active (exists now) | Ken Nishikawa: No Answer | Takehiro Terashima: No Answer | Masatoshi Minamisawa: DO have relevant financial relationships ; Employee:Alexion Pharma, GK:Active (exists now) | koji yoshie: DO NOT have relevant financial relationships | Takenori Aoki: No Answer | Yukari Okuma: No Answer | Kazuhiro Kimura: No Answer | Yasushi Ueki: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Clinical Decision Making in Pulmonary Hypertension: Navigating the Evolving Landscape

Saturday, 11/08/2025 , 12:15PM - 01:30PM

Moderated Digital Poster Session

More abstracts on this topic:
Association Between Genetics Variants And Clinical Outcomes In Patients With Left Ventricular Assist Device

Silver Elizabeth, Hong Kimberly, Tran Hao, Pretorius Victor, Kearns Mark, Urey Marcus, Adler Eric, Bui Quan

Bile Acid Dysregulation in Response to Right Heart Failure and Hepatic Congestion

Park Arick, Yang Bin, Parvathaneni Adeesh, Fu Christina, Byrnes Kathleen, Haeusler Rebecca, Schilling Joel

You have to be authorized to contact abstract author. Please, Login
Not Available